In REACH, a consistent ramucirumab treatment benefit compared with placebo was demonstrated for advanced HCC patients with AFP ≥ 400 ng/ml, whereas no meaningful OS treatment effect was observed in patients with AFP < 400 ng/ml. Here, AFP is linked to hepatocellular carcinoma.